Cardio-Oncology

Researchers at Heart Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities Cardio‐Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies Response by Omland et al to Letter Regarding Article, “Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial” Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191 Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191 Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging Restarting Immune Checkpoint Inhibitors After ICI Myocarditis: A Prospective Cohort Letter by Liu and Li Regarding Article, “Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke” Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity